ClinicalTrials.gg
CompletedNCT00195559Updated Dec 27, 2007

Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder

A Phase 3 interventional study of Levonorgestrel/Ethinyl Estradiol in Premenstrual Syndrome and Menstruation Disturbances, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 52 sites in 12 countries. Open to female participants aged 18 Years to 49 Years. Per ClinicalTrials.gov, last updated 2007-12-27.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
526
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
Female
01

Study summary

The purpose of this study is to determine whether Levonorgestrel/Ethinyl Estradiol (LNG/EE) is effective in treating the symptoms of severe Premenstrual Dysphoric Disorder.

02

Conditions studied

  • Premenstrual Syndrome
  • Menstruation Disturbances

Keywords

  • Premenstrual Syndrome (PMS)
  • Hormone Therapy
03

In context

Premenstrual Syndrome

177 studies on the registry are indexed under Premenstrual Syndrome; 32 are open to participants now.

This study's planned enrollment of 526 is above the median of 70 across 154 interventional studies indexed under Premenstrual Syndrome.

Browse Premenstrual Syndrome studies →

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy, women aged 18 to 49 years.
  • History of severe PMS symptoms over the last year, as determined by the investigator.
  • Regular 21 to 35 day menstrual cycle for 2 months prior to first study visit.

Exclusion criteria

Exclusion Criteria:

  • Major depressive disorder requiring antidepressant treatment or hospitalization within the last 3 years.
  • to combination oral .
  • Use of antidepressants/anxiolytics within 10 days of screening and for the duration of the study.

Other exclusion applies.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
526 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in average Daily Record of Severity of Problems (DRSP) 21-item total daily score

Secondary outcomes

  1. Change from baseline in DRSP 21-item daily score based on the 5 days with the highest DRSP scores in each "estimated" treatment cycle

07

Study locations

52 sites
  • Buenos Aires, Argentina
  • Ciudad Autonoma de Buenos Aires, Argentina
  • Cordoba, Argentina
  • Rosario-Santa Fe, Argentina
  • Curitiba, Brazil
  • Goiania, Brazil
  • Porto Alegre, Brazil
  • Salvador, Brazil
  • Sao Paulo, Brazil
  • Sorocaba, Brazil
  • Santiago, Chile
  • Temuco, Chile
  • Arhus, Denmark
  • Frederiksberg, Denmark
  • Kobenhavn NV, Denmark
  • Rungsted Kyst, Denmark
  • Helsinki, Finland
  • Kuopio, Finland
  • Oulu, Finland
  • Turku, Finland
  • Berlin, Germany
  • Bonn, Germany
  • Hamburg, Germany
  • Hannover, Germany
  • Lomas de Virreyes, D.f., Mexico
  • Guadalajara, Jalisco, Mexico
  • Zapopan, Jalisco, Mexico
  • Monterrey, N.l., Mexico
  • San Luis Potosi, SLP, Mexico
  • Mexico City, Mexico
  • Amsterdam, Netherlands
  • Apeldoorn, Netherlands
  • Den Helder, Netherlands
  • Enschede, Netherlands
  • Nieuwegein, Netherlands
  • Bialystok, Poland
  • Gdansk, Poland
  • Myslowice, Poland
  • Poznan, Poland
  • Warszawa, Poland
  • S
    Bucuresti, Romania
  • Cluj-Napoca, Romania
  • Iasi, Romania
  • Goteborg, Sweden
  • Stockholm, Sweden
  • Umea, Sweden
  • Uppsala, Sweden
  • Conwell, United Kingdom
  • Fowey, United Kingdom
  • London, United Kingdom
  • Plymouth, United Kingdom
  • St. Austell, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 19, 2005
Start
Sep 2005
CompletionActual
Dec 2007
Last update
Dec 27, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00195559
First posted
Sep 19, 2005
Start date
Sep 2005
Completion
Dec 2007
Last update
Dec 27, 2007

Study contacts

Trial Manager
principal investigator · For Argentina, Chile, scheima@wyeth.com
Trial Manager
principal investigator · For Brazil, xavierl@wyeth.com
Trial Manager
principal investigator · For Denmark, Finland, Sweden, MedInfoNord@wyeth.com
Trial Manager
principal investigator · For Germany, MedinfoDEU@wyeth.com
Trial Manager
principal investigator · For Mexico, gomezlj@wyeth.com
Trial Manager
principal investigator · For Netherlands, trials-NL@wyeth.com
Trial Managersp
principal investigator · For Poland, WPWZMED@wyeth.com
Trial Manager
principal investigator · For Romania, WPVIMED@wyeth.com
Trial Manager
principal investigator · For UK, ukmedinfo@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol

Start the discussion